Can You Have Botox While on Mounjaro? What Clinicians Currently Know

What the current evidence actually says about combining these treatments

Neither the MHRA nor NHS clinical guidance for tirzepatide identifies botulinum toxin as a contraindicated or cautioned concurrent treatment. The NHS medicines page for tirzepatide covers known interactions (primarily with oral contraceptives and other drugs with narrow therapeutic windows) and injectable aesthetic treatments are not among them. Similarly, there is no entry in the Mounjaro SmPC or BNF flagging botulinum toxin as a concern.

That absence of a recorded interaction is genuinely reassuring. Botox works locally at the neuromuscular junction; tirzepatide works systemically on GIP and GLP-1 receptors involved in appetite regulation and blood-sugar control. The two pathways do not obviously collide.

Where evidence does exist, it comes from dermatology practice rather than controlled trials. Clinicians working with patients on GLP-1 medicines have noted that reduced subcutaneous fat and changes in skin quality can emerge during significant weight loss, both of which could alter how botulinum toxin sits and spreads in treated tissue. This is an observation from practice, not a trial finding, and it applies more meaningfully to high-dose, long-term treatment than to someone a few weeks in. The SURMOUNT-1 trial (published in the New England Journal of Medicine) showed average weight reductions of around 20% at the highest dose over 72 weeks, the kind of change that genuinely reshapes the face. An aesthetic practitioner who is not told about that degree of ongoing loss may plan treatment based on a facial architecture that looks different in six months.

The practical conclusion: tell your practitioner. Both of them.

How Mounjaro's effects on circulation and tissue may be relevant to a Botox appointment

Tirzepatide slows gastric emptying, but its broader metabolic effects also include changes in how the body handles fat stores and, in some studies, alterations in microvascular circulation. Neither effect has been formally linked to botulinum toxin complications, but they are relevant context for the practitioner holding the needle.

Bruising at injection sites is a common Botox side effect at the best of times. There is some clinical discussion about whether GLP-1 receptor agonists could influence platelet aggregation or capillary fragility, though this remains an area of active research rather than established fact. You can read more about the nuances of this question on our page covering whether Mounjaro affects Botox outcomes. The conservative approach, recommended by many aesthetic doctors, is to avoid Botox in the week before or after a Mounjaro injection if you bruise easily — not because of a proven risk, but because the timing is easy to manage and eliminates one variable.

Dehydration is another consideration. Nausea and reduced appetite are common in the early weeks of Mounjaro treatment, and some people eat and drink less than usual while settling in. Good hydration supports skin integrity and healing; arriving at a Botox appointment dehydrated is suboptimal regardless of what medicines you take. The full Mounjaro treatment overview covers the adjustment period in more detail.

The facial-volume conversation your aesthetician needs to have with you

This is the most practically significant consideration, and it is frequently overlooked. Rapid or substantial weight loss changes facial fat distribution. The temples, cheeks, and under-eye area tend to hollow first; jowl tissue may shift. A Botox plan designed around your face at the start of Mounjaro treatment may produce a different result (sometimes a less flattering one) once weight loss is well underway.

Experienced aesthetic practitioners increasingly ask patients whether they are on weight-loss medication before treating them, for this reason. If your practitioner does not ask, volunteer the information. The same applies to dermal fillers, which are even more affected by volume change than botulinum toxin.

For a detailed comparison of how tirzepatide interacts with aesthetic medicine, the Botox and Mounjaro page goes into more depth on the facial-volume question specifically. If you are weighing up whether Mounjaro might be suitable for you in the first place, the clinical eligibility guide is a useful starting point, a GPhC-registered prescriber at our pharmacy reviews every consultation personally, on the same day it is submitted.

Mounjaro arrives in a pre-filled KwikPen, in plain unbranded packaging via tracked DPD delivery, so there is nothing about receiving the treatment that imposes on other appointments or routines. Managing an aesthetic appointment alongside it is straightforwardly a matter of good communication between your care team and your practitioner. For questions about pausing treatment around any procedure, taking a break from Mounjaro is something our prescribers can advise on during your clinical review. You might also find our frequently asked questions page helpful for general queries about how treatment works, including whether Mounjaro is discontinued, which is one of the queries our team receives most regularly.